Novo Nordisk A/S Peer Comparison
Metric | Value | Ranking | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $486.3 Billion | 1/21 | NVO $486.3B |
VRTX $121.6B |
REGN $89.9B |
SGEN $43.2B |
ALNY $34.8B |
BNTX $25.9B |
MRNA $20.6B |
BMRN $12.6B |
SRPT $11.7B |
MDGL $7.2B |
RETA $6.6B |
CRSP $4.3B |
TGTX $3.8B |
NTLA $1.5B |
NVAX $1.5B |
ICPT $794.7M |
CVAC $607.9M |
TERN $599.5M |
DNA $424.0M |
HEPA $3.7M |
CWBR $1.4M |
Gross Margin | 85% | 8/21 | ICPT 100% |
RETA 96% |
MDGL 96% |
NVAX 91% |
ALNY 90% |
TGTX 89% |
VRTX 86% |
NVO 85% |
SRPT 85% |
REGN 83% |
BMRN 80% |
SGEN 75% |
NTLA 63% |
BNTX 54% |
DNA 45% |
MRNA 35% |
CWBR 0% |
HEPA 0% |
TERN 0% |
CRSP -100% |
CVAC -100% |
Profit Margin | 29% | 4/21 | RETA 100% |
REGN 40% |
NVAX 39% |
NVO 29% |
BMRN 15% |
TGTX 9% |
SRPT 2% |
CWBR 0% |
HEPA 0% |
TERN 0% |
ALNY -3% |
ICPT -3% |
SGEN -33% |
VRTX -100% |
MDGL -100% |
NTLA -100% |
CRSP -100% |
MRNA -100% |
BNTX -100% |
CVAC -100% |
DNA -100% |
EBITDA margin | 51% | 1/21 | NVO 51% |
NVAX 42% |
REGN 34% |
BMRN 18% |
TGTX 12% |
ALNY 10% |
SRPT 3% |
ICPT -3% |
SGEN -34% |
CWBR -100% |
HEPA -100% |
TERN -100% |
VRTX -132% |
DNA -237% |
RETA -356% |
CVAC -474% |
BNTX -505% |
MRNA -549% |
MDGL -1110% |
NTLA -1961% |
CRSP -28320% |
Quarterly Revenue | $10.0 Billion | 1/21 | NVO $10.0B |
REGN $3.5B |
VRTX $2.6B |
BMRN $708.7M |
ALNY $659.8M |
SGEN $648.7M |
NVAX $415.5M |
SRPT $362.9M |
MRNA $241.0M |
BNTX $142.1M |
ICPT $88.8M |
TGTX $73.5M |
DNA $56.2M |
RETA $22.7M |
CVAC $15.9M |
MDGL $14.6M |
NTLA $7.0M |
CRSP $517,000 |
CWBR $0 |
HEPA $0 |
TERN $0 |
Quarterly Earnings | $3.0 Billion | 1/21 | NVO $3.0B |
REGN $1.4B |
RETA $193.0M |
NVAX $162.4M |
BMRN $107.2M |
TGTX $6.9M |
SRPT $6.5M |
ICPT -$2.8M |
HEPA -$3.9M |
CWBR -$4.3M |
ALNY -$16.9M |
TERN -$22.7M |
CVAC -$80.1M |
CRSP -$126.4M |
NTLA -$147.0M |
MDGL -$152.0M |
SGEN -$215.8M |
DNA -$217.2M |
BNTX -$892.2M |
MRNA -$1.3B |
VRTX -$3.6B |
Quarterly Free Cash Flow | $5.5 Billion | 1/21 | NVO $5.5B |
BNTX $1.6B |
NVAX $311.1M |
REGN $143.1M |
ALNY $116.1M |
BMRN $96.9M |
TGTX $5.5M |
ICPT $3.9M |
MDGL -$0 |
CWBR -$1.8M |
HEPA -$10.9M |
SRPT -$14.2M |
TERN -$16.2M |
NTLA -$59.2M |
RETA -$70.2M |
SGEN -$79.8M |
CRSP -$96.3M |
CVAC -$105.8M |
DNA -$111.4M |
MRNA -$1.5B |
VRTX -$3.8B |
Trailing 4 Quarters Revenue | $38.1 Billion | 2/21 | BMRN $648.1B |
NVO $38.1B |
REGN $13.5B |
VRTX $10.3B |
MRNA $5.1B |
BNTX $3.0B |
ALNY $2.3B |
SGEN $2.3B |
SRPT $1.5B |
NVAX $822.7M |
TGTX $346.7M |
ICPT $317.7M |
CRSP $201.0M |
DNA $184.3M |
CVAC $71.8M |
NTLA $46.0M |
RETA $24.4M |
MDGL $14.6M |
CWBR $0 |
HEPA $0 |
TERN $0 |
Trailing 4 Quarters Earnings | $13.3 Billion | 2/21 | NVO $10.0B |
REGN $3.5B |
VRTX $2.6B |
BMRN $708.7M |
ALNY $659.8M |
SGEN $648.7M |
NVAX $415.5M |
SRPT $362.9M |
MRNA $241.0M |
BNTX $142.1M |
ICPT $88.8M |
TGTX $73.5M |
DNA $56.2M |
RETA $22.7M |
CVAC $15.9M |
MDGL $14.6M |
NTLA $7.0M |
CRSP $517,000 |
CWBR -$0 |
HEPA -$0 |
TERN -$0 |
Quarterly Earnings Growth | 3% | 9/21 | RETA 362% |
NVAX 180% |
SRPT 127% |
TGTX 114% |
ALNY 94% |
HEPA 72% |
REGN 48% |
MRNA 7% |
NVO 3% |
CVAC -8% |
SGEN -13% |
NTLA -19% |
DNA -25% |
TERN -27% |
CWBR -59% |
CRSP -63% |
MDGL -77% |
BMRN -100% |
ICPT -101% |
BNTX -326% |
VRTX -492% |
Annual Earnings Growth | 14% | 8/21 | TGTX 159% |
SRPT 103% |
ALNY 91% |
RETA 72% |
NVAX 64% |
HEPA 47% |
REGN 26% |
NVO 14% |
CWBR 1% |
CRSP -12% |
DNA -14% |
CVAC -15% |
TERN -16% |
SGEN -26% |
NTLA -27% |
MDGL -60% |
BMRN -63% |
VRTX -116% |
ICPT -124% |
BNTX -139% |
MRNA -413% |
Quarterly Revenue Growth | 25% | 7/21 | RETA 2885% |
TGTX 357% |
ALNY 107% |
CVAC 91% |
SRPT 39% |
SGEN 27% |
NVO 25% |
ICPT 14% |
REGN 12% |
VRTX 6% |
MDGL 0% |
CWBR 0% |
HEPA 0% |
TERN 0% |
NVAX -2% |
BNTX -23% |
MRNA -30% |
DNA -30% |
NTLA -49% |
CRSP -99% |
BMRN -100% |
Annual Revenue Growth | 20% | 7/21 | TGTX 778% |
RETA 596% |
CVAC 126% |
ALNY 84% |
SRPT 47% |
NVAX 23% |
NVO 20% |
SGEN 15% |
BMRN 9% |
ICPT 8% |
VRTX 7% |
REGN 7% |
MDGL 0% |
CWBR 0% |
HEPA 0% |
TERN 0% |
NTLA -11% |
MRNA -15% |
BNTX -33% |
DNA -43% |
CRSP -46% |
Cash On Hand | $7.8 Billion | 2/21 | BNTX $11.4B |
NVO $7.8B |
VRTX $4.6B |
MRNA $2.5B |
REGN $1.9B |
BMRN $972.2M |
ALNY $968.5M |
DNA $732.7M |
NVAX $690.6M |
MDGL $494.6M |
CRSP $484.5M |
SGEN $428.6M |
SRPT $383.6M |
CVAC $222.7M |
NTLA $130.8M |
ICPT $102.7M |
TERN $91.5M |
TGTX $82.9M |
RETA $48.8M |
CWBR $6.2M |
HEPA $2.1M |
Short Term Debt | $804.1 Million | 1/21 | NVO $804.1M |
BMRN $505.5M |
ALNY $103.6M |
SRPT $91.5M |
BNTX $38.8M |
MRNA $25.0M |
NTLA $19.0M |
CRSP $16.5M |
NVAX $9.4M |
CVAC $5.6M |
RETA $2.5M |
TGTX $1.3M |
MDGL $557,000 |
TERN $249,000 |
HEPA $154,090 |
VRTX -$0 |
REGN -$0 |
SGEN -$0 |
ICPT -$0 |
CWBR -$0 |
DNA -$0 |
Long Term Debt | $7.6 Billion | 1/21 | NVO $7.6B |
ALNY $2.4B |
REGN $2.0B |
MRNA $1.2B |
SRPT $1.1B |
VRTX $933.4M |
BMRN $594.1M |
DNA $452.3M |
BNTX $241.0M |
ICPT $223.9M |
CRSP $214.9M |
NVAX $168.8M |
RETA $163.5M |
SGEN $113.5M |
TGTX $102.5M |
NTLA $87.3M |
MDGL $0 |
CWBR $0 |
HEPA $0 |
CVAC $0 |
TERN $0 |
PE | 36.67 | 3/21 | SRPT 248.15 |
TGTX 39.42 |
NVO 36.67 |
REGN 20.79 |
BMRN 0.61 |
NVAX -1.00 |
VRTX -1.00 |
ALNY -1.00 |
RETA -1.00 |
SGEN -1.00 |
ICPT -1.00 |
MDGL -1.00 |
NTLA -1.00 |
CRSP -1.00 |
CWBR -1.00 |
HEPA -1.00 |
MRNA -1.00 |
BNTX -1.00 |
CVAC -1.00 |
TERN -1.00 |
DNA -1.00 |
PS | 86.64 | 3/21 | MDGL 493.66 |
RETA 269.17 |
NVO 86.64 |
NTLA 33.46 |
CRSP 21.43 |
SGEN 18.76 |
ALNY 14.85 |
VRTX 11.78 |
TGTX 10.88 |
BNTX 7.97 |
SRPT 7.80 |
CVAC 7.70 |
REGN 6.66 |
MRNA 4.08 |
ICPT 2.50 |
DNA 2.30 |
NVAX 1.77 |
BMRN 0.02 |
CWBR -1.00 |
HEPA -1.00 |
TERN -1.00 |
PB | 29.30 | 2/21 | RETA 75.22 |
NVO 29.30 |
TGTX 21.24 |
SGEN 16.92 |
ICPT 11.06 |
SRPT 10.90 |
MDGL 8.43 |
VRTX 8.23 |
REGN 3.19 |
TERN 2.74 |
BMRN 2.38 |
CRSP 2.18 |
MRNA 1.76 |
NTLA 1.58 |
CVAC 1.47 |
BNTX 1.24 |
HEPA 1.03 |
DNA 0.51 |
CWBR 0.15 |
NVAX 0.00 |
ALNY 0.00 |
PC | 62.41 | 3/21 | RETA 134.44 |
SGEN 100.70 |
NVO 62.41 |
REGN 46.60 |
TGTX 45.49 |
ALNY 35.95 |
SRPT 30.59 |
VRTX 26.55 |
MDGL 14.61 |
BMRN 12.94 |
NTLA 11.75 |
CRSP 8.89 |
MRNA 8.31 |
ICPT 7.74 |
TERN 6.55 |
CVAC 2.73 |
BNTX 2.27 |
NVAX 2.11 |
HEPA 1.73 |
DNA 0.58 |
CWBR 0.23 |
Liabilities to Equity | 2.28 | 3/21 | RETA 4.76 |
ICPT 4.47 |
NVO 2.28 |
SRPT 2.18 |
TGTX 1.26 |
DNA 0.95 |
HEPA 0.69 |
CVAC 0.48 |
SGEN 0.42 |
VRTX 0.36 |
BMRN 0.34 |
MRNA 0.34 |
CWBR 0.32 |
REGN 0.28 |
MDGL 0.28 |
NTLA 0.23 |
CRSP 0.18 |
BNTX 0.17 |
TERN 0.06 |
NVAX 0.00 |
ALNY 0.00 |
ROA | 0.04 | 4/21 | BMRN 292% | TGTX 24% | REGN 12% | NVO 4% | SRPT 1% | VRTX -2% | ALNY -2% | BNTX -3% | CRSP -11% | ICPT -15% | NVAX -16% | RETA -16% | SGEN -21% | MRNA -37% | TERN -42% | NTLA -43% | MDGL -46% | CVAC -55% | DNA -55% | CWBR -99% | HEPA -472% |
ROE | 0.12 | 6/21 | ALNY 2378% |
BMRN 390% |
NVAX 68% |
TGTX 54% |
REGN 15% |
NVO 12% |
SRPT 4% |
VRTX -3% |
BNTX -3% |
CRSP -13% |
SGEN -29% |
TERN -44% |
MRNA -50% |
NTLA -52% |
MDGL -60% |
CVAC -81% |
ICPT -82% |
RETA -94% |
DNA -108% |
CWBR -131% |
HEPA -796% |
Current Ratio | 1.44 | 17/21 | TERN 18.93 |
BNTX 7.02 |
CRSP 6.52 |
NTLA 5.40 |
REGN 4.58 |
MDGL 4.53 |
CWBR 4.17 |
BMRN 3.97 |
MRNA 3.95 |
VRTX 3.76 |
SGEN 3.35 |
CVAC 3.09 |
HEPA 2.45 |
DNA 2.05 |
TGTX 1.79 |
SRPT 1.46 |
NVO 1.44 |
ICPT 1.22 |
RETA 1.21 |
ALNY 1.00 |
NVAX 0.81 |
Quick Ratio | 0.24 | 21/21 | SRPT 248.15 |
TGTX 39.42 |
NVO 36.67 |
REGN 20.79 |
BMRN 0.61 |
NVAX -1.00 |
VRTX -1.00 |
ALNY -1.00 |
RETA -1.00 |
SGEN -1.00 |
ICPT -1.00 |
MDGL -1.00 |
NTLA -1.00 |
CRSP -1.00 |
CWBR -1.00 |
HEPA -1.00 |
MRNA -1.00 |
BNTX -1.00 |
CVAC -1.00 |
TERN -1.00 |
DNA -1.00 |
Long Term Debt to Equity | 0.46 | 6/21 | ICPT} 3.12 |
RETA} 1.87 |
SRPT} 1.05 |
TGTX} 0.58 |
DNA} 0.54 |
NVO} 0.46 |
BMRN} 0.11 |
CRSP} 0.11 |
MRNA} 0.11 |
NTLA} 0.09 |
REGN} 0.07 |
VRTX} 0.06 |
SGEN} 0.04 |
BNTX} 0.01 |
MDGL} 0.00 |
CWBR} 0.00 |
HEPA} 0.00 |
CVAC} 0.00 |
TERN} 0.00 |
NVAX} -0.39 |
ALNY} -771.20 |
Debt to Equity | 0.51 | 6/21 | ICPT 3.12 |
RETA 1.90 |
SRPT 1.27 |
TGTX 0.63 |
DNA 0.54 |
NVO 0.51 |
BMRN 0.21 |
CRSP 0.12 |
NTLA 0.11 |
MRNA 0.11 |
REGN 0.10 |
CVAC 0.10 |
VRTX 0.06 |
SGEN 0.04 |
HEPA 0.04 |
BNTX 0.01 |
MDGL 0.00 |
CWBR 0.00 |
TERN 0.00 |
NVAX -0.54 |
ALNY -883.03 |
Burn Rate | 112.36 | 1/21 | NVO 112.36 |
BMRN 22.62 |
BNTX 11.41 |
ICPT 8.75 |
ALNY 7.05 |
SRPT 6.21 |
TERN 4.01 |
CRSP 3.48 |
MDGL 3.25 |
DNA 3.11 |
CVAC 2.49 |
SGEN 1.95 |
MRNA 1.86 |
CWBR 1.43 |
VRTX 1.26 |
NTLA 0.84 |
HEPA 0.53 |
RETA -0.26 |
REGN -1.43 |
NVAX -4.51 |
TGTX -33.83 |
Cash to Cap | 0.02 | 17/21 | CWBR 4.35 |
DNA 1.73 |
HEPA 0.58 |
NVAX 0.47 |
BNTX 0.44 |
CVAC 0.37 |
TERN 0.15 |
ICPT 0.13 |
MRNA 0.12 |
CRSP 0.11 |
NTLA 0.09 |
BMRN 0.08 |
MDGL 0.07 |
VRTX 0.04 |
ALNY 0.03 |
SRPT 0.03 |
NVO 0.02 |
REGN 0.02 |
TGTX 0.02 |
RETA 0.01 |
SGEN 0.01 |
CCR | 1.86 | 3/21 | HEPA 2.78 |
NVAX 1.92 |
NVO 1.86 |
CVAC 1.32 |
MRNA 1.14 |
VRTX 1.07 |
BMRN 0.90 |
TGTX 0.80 |
CRSP 0.76 |
TERN 0.71 |
DNA 0.51 |
CWBR 0.42 |
NTLA 0.40 |
SGEN 0.37 |
REGN 0.10 |
MDGL 0.00 |
RETA -0.36 |
ICPT -1.38 |
BNTX -1.85 |
SRPT -2.20 |
ALNY -6.88 |
EV to EBITDA | 2.21 | 7/21 | SRPT} 1057.61 |
ALNY} 574.66 |
TGTX} 427.67 |
BMRN} 97.81 |
REGN} 74.65 |
NVAX} 5.79 |
NVO} 2.21 |
CWBR} -1.00 |
HEPA} -1.00 |
TERN} -1.00 |
DNA} -1.08 |
CVAC} -7.33 |
NTLA} -11.09 |
MRNA} -14.65 |
CRSP} -27.70 |
BNTX} -28.09 |
VRTX} -33.98 |
MDGL} -41.42 |
RETA} -82.50 |
SGEN} -191.83 |
ICPT} -331.82 |
EV to Revenue | 2.00 | 15/21 | MDGL 459.91 |
RETA 273.97 |
NTLA 32.92 |
CRSP 20.17 |
SGEN 18.62 |
ALNY 15.59 |
VRTX 11.43 |
TGTX 10.96 |
SRPT 8.45 |
CVAC 7.02 |
REGN 6.72 |
BNTX 6.20 |
MRNA 3.84 |
ICPT 2.88 |
NVO 2.00 |
NVAX 1.22 |
DNA 0.78 |
BMRN 0.02 |
CWBR -1.00 |
HEPA -1.00 |
TERN -1.00 |